Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SCYX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSCYNEXIS board member Steven C. Gilman to retire at 2026 annual meeting
Filed April 20, 2026 · Period ending April 16, 2026 · ~1 min read
Key Changes
-
medium
Dr. Steven C. Gilman, current Chair of the Compensation Committee, will retire from the Board of Directors when his term expires at the 2026 annual stockholder meeting and will not seek reelection.
Item 5.02 verify on EDGAR → -
low
The company confirmed Dr. Gilman's retirement is voluntary with no disagreements regarding operations, policies, strategy, management, or board matters.
Item 5.02 verify on EDGAR →
Summary
SCYNEXIS disclosed that board member Dr. Steven C. Gilman will retire when his current term expires at the company's 2026 annual stockholder meeting. Dr. Gilman currently serves as Chair of the Compensation Committee and sits on the Nominating and Corporate Governance Committee. The company explicitly stated his departure is a voluntary retirement with no underlying disputes.
For retail investors, this represents routine board turnover at a small biotech company. The departure appears amicable and planned, reducing concerns about internal conflicts or strategic disagreements. However, losing an experienced board member who chairs a key committee means SCYNEXIS will need to fill leadership gaps in board governance.
Watch for the company's proxy statement ahead of the 2026 annual meeting to see who the board nominates as replacements and how committee leadership roles are reassigned. The quality and experience of new board members will signal whether SCYNEXIS can maintain strong governance oversight.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Dr. Gilman’s resignation was not the result of any disagreement with the Company on any matter related to the Company’s operations, policies, practices or strategy, the Company’s management or the Board.
The company explicitly disclosed that Dr. Gilman's departure is a voluntary retirement with no underlying disputes or disagreements regarding company operations, policies, strategy, management, or board matters. This standard disclosure helps clarify the departure is amicable and routine.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify